The once-daily therapy, co-developed with Medivation, was filed in the country in May 2013 and approved in the US in August 2012 and in the EU in June 2013 for metastatic CRPC in patients who have previously received docetaxel.
written on 24.03.2014
Xtandi approved in Japan for CRPC
